+44 20 3868 9735
Centre of Nuclear Medicine, Argentina
Keynote: J Mol Imaging Dynam
Purpose: To review the bibliography and our results in the usefulness of 18 F-Choline PET fused with CT in prostate cancer to diagnose bone metastasis. Prostate cancer is the most common cancer in men in our country. Methods: 18Fluorcholine ( 18FCH) PET CT was performed in 27 patients with prostate cancer using 0,035 Mci/kg in our department of nuclear medicine since 31/ 01/2017 to 01/08/2018, we included patients with biopsy-proven prostate cancer with rise in PSA for restaging. In our patient series, biochemical recurrence of prostate cancer was considered present when the levels of serum PSA measured after surgery or radiotherapy and/or hormonal therapy exceeded 0.1 ng /ml. Results were correlated with clinical, bio chemical and imaging follow up. Results: We studied 27 patients. We found bone metastases in 10 patients, 15 patients were high risk patients, considering high risk when PSA was 10 or more and Gleason was 7 or more. We found hypermethabolic bone metastasis in 9 of this patients, only 2 of them had blastic images in CT with normal 18 FCH uptake, however in 2 of the 10 patients with multiple bone metastasis, at least 50%of the lesions had no 18 FCH uptake. They were predominantly blastic. Conclusion: 18 FCH PET CT is a very useful method for diagnosing bone metastasis in Prostate Cancer biochemical recurrence, however when they are very hyper dense in CT they may be not uptake 18 FCH, in those cases the CT was used for bone metastasis diagnostic.
Dr Mariela Agolti is a certificated Nuclear Medicine Specialist. She serves as the Medical Director of Centro Medicina Nuclear Clinica Modelo, Parana, E Rios Argentina. She is also the Director of University Technology Career Bioingeneering University and is the member of WARMTH.
E-mail: [email protected]